Affiris AG, the Austrian developer of therapeutic peptide vaccines, has appointed Arne von Bonin to the executive board of the company, along with Oliver Siegel, as part of the transition of the company’s founders to a supervisory role. Dr von Bonin joined the company in 2012 as head of preclinical development and discovery. Before joining Affiris he held positions in research at Schering AG and in R&D management at Bayer Healthcare AG.
Dr von Bonin and Mr Siegel will replace Walter Schmidt and Frank Mattner who founded Affiris and will move to the supervisory board.
Affiris announced the management changes on 5 February 2015.
Copyright 2015 Evernow Publishing Ltd